Molcure is a biotechnology company that focuses on accelerating drug discovery through the integration of AI-driven science and molecular engineering. The company offers a platform that combines machine learning, laboratory automation, and a proprietary database to generate diverse antibodies and peptides. Molcure primarily serves the biopharmaceutical research sector, partnering with companies to discover therapeutics. It was founded in 2013 and is based in Kawasaki, Japan.

Generate Biomedicines serves as a therapeutics company that operates at the intersection of machine learning, biological engineering, and medicine, focusing on pioneering generative biology to create breakthrough medicines. The company's main offerings include the development of novel medicines. Generate Biomedicines primarily serves the biopharmaceutical industry. It was founded in 2018 and is based in Somerville, Massachusetts.

Adimab operates in biologics discovery and engineering within the biotechnology sector, focusing on antibodies and multispecifics. The company utilizes a yeast-based platform for the discovery and optimization of human monoclonal antibodies, bispecific antibodies, and T cell engagers, which are relevant for developing protein-based therapeutics. Adimab collaborates with pharmaceutical companies, biotech firms, and academic institutions to develop therapeutic leads. It was founded in 2007 and is based in Lebanon, New Hampshire.

Insitro is a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology. The company has a machine learning platform that combines in vitro cellular data with human clinical data to identify insights and interventions in metabolism, oncology, and neuroscience. Insitro's approach uses technology to model disease states and design therapeutic interventions. It was founded in 2018 and is based in South San Francisco, California.

Vilya operates as a computational biotechnology company. The company focuses on creating medicines using advanced computational approaches to target disease biology, leveraging machine learning and computational chemistry to design molecular structures not found in nature. It primarily serves the healthcare and pharmaceutical industries. It was founded in 2022 and is based in Seattle, Washington.

neoX Biotech is a biotech company that integrates artificial intelligence with biophysics to innovate in drug research and development. The company specializes in the discovery and development of macromolecular and multispecific drugs, with a focus on immuno-oncology, leveraging a sophisticated platform for characterizing protein-protein interactions. neoX Biotech collaborates with global biomedical companies to enhance drug R&D pipelines. It was founded in 2018 and is based in Beijing, China.